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combination of surgery, chemotherapy and radiation therapy. 
The side effects still are the main limitation of brain tumors’ 
treatment by radiotherapy and do not allow the dose 
escalation needed to treat these highly radio-resistant 
tumors. In this research program, we propose a new FLASH 
radiotherapy modality based on the dose delivery at ultrahigh 
dose-rate (above 50Gy/s), which has shown an important 
differential effect with the protection of normal tissues and 
stem cells and an efficient antitumor effect (Favaudon et al. 
2014).  
Materials and Methods: Two LINACs prototypes are used: a 
4.5 MeV (Institut Curie) and a 6 MeV (CHUV) to investigate 
the normal brain response and the antitumor effect of FLASH 
irradiation on GBM models in a preclinical study with an 
ultimate aim to apply this treatment to GBM bearing 
patients. For the studies on normal brain, C57Bl6/J mice 
were irradiated at the whole brain level at single doses 
ranging from 10 to 80 Gy FLASH (>50Gy/s), at 10 Gy CONV 
(0.04Gy/s) and sham irradiated (6 mice in each group). Two 
months post-irradiation, cognitive tests were performed on 
mice to evaluate the mid-term memory with a novel object 
recognition test (Acharya et al. 2009) and brains were 
sampled. Two hours before the sampling, mice were injected 
with BrdU, brains were collected and immunohistochemistry 
and NSCs quantification were performed on brain sections. To 
evaluate the FLASH antitumor effect, human GBM were 
engrafted to nude mice. The tumors were locally irradiated 
at 10 Gy CONV, from 10 to 30 Gy FLASH and sham irradiated. 
Tumor growth delay was measured.  
Results: Our preliminary results show that 50Gy FLASH 
irradiation on the whole brain does not induce any 
macroscopic toxicity nor mice’s health alteration whereas a 
pan-encephalic irradiation of 10Gy CONV is the maximum 
tolerated dose for long term follow-up. The cognitive tests’ 
results show a drop in cognitive skills after 10Gy CONV 
irradiation whereas mid-term visual memorization is not 
significantly affected at 50Gy FLASH. In correlation, two 
months after irradiation, the quantification of NSCs shows 
their preservation in the SGZ at doses up to 20Gy FLASH 
whereas 10Gy CONV eradicates all the hippocampal NSCs at 
the same timepoint. Astrocytic toxicity has also been 
investigated and shows that 10Gy CONV irradiation induces a 
high level of gliosis and astrocytes’ remodeling whereas few 
gliosis and astrocytes’ modifications are observed after 50Gy 
FLASH. At the tumor level and at similar doses, the FLASH 
and CONV irradiations induce a similar growth retardation. 
Nevertheless, the FLASH irradiation’s innocuousness on 
normal tissue does allow a dose escalation and thus an 
enhancement of the tumor growth delay. We are currently 
escalading the dose to achieve the tumor control. 
Conclusions: Altogether these results suggest that the FLASH 
radiotherapy allows the delivery of very high doses to the 
whole brain, sparing normal tissues and NSCs and eradicating 
tumor cells. In the follow up of these preliminary 
experiments we are developing orthotopic and spontaneous 
GBM models in mice (in collaboration with K. Shchors and D. 
Hanahan, EPFL) to define the molecular basis of the FLASH 
differential effect. 
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Purpose/Objective: To evaluate clinical-radiological 
response and outcome in soft tissue sarcomas of extremities, 
in patients treated with neoadjuvant radiochemotherapy. 
Materials and Methods: 74 patients (25 females, 49 males; 
median age 53.7 years, range: 27-87), were treated with 
neoadjuvant chemotherapy (CT) and radiotherapy (RT). 
Selection criteria were diseases of large dimension or in close 
proximity of critical structures such as nerves or vessels. 
Based on RMN images, the Gross Tumor Volume (GTV), 
defined as the macroscopic volume of disease visible in the 
T1-weighted sequences, was included. MRI images were 
merged with those of TC-simulation. For CTV definition, an 
expansion of 4 cm in cranio-caudal (except where anatomical 
barriers were present) and 1 cm in anterior-posterior and 
lateral-side was given to the GTV. PTV was defined as CTV + 
1 cm isotropically. All patients underwent CT, MRI +/- PET 
before RT, at the end of RT (before surgery) and during 
follow-up (FU). 
Results: At preoperative MRI revaluation the volumetric size 
of the tumor showed an average reduction of 34% (range 
+83.0% to -88.8%). Only 24 patients (32.4%) needed an 
adjuvant RT-boost for marginal or intralesional margins. Only 
three patients had local relapse at 3-13-31 months after 
surgery and were treated with surgical resection or 
brachytherapy, with local control of the disease in the 
following radiological-clinical controls. Patients with smaller 
tumors (< median) and better clinical response (> median) 
showed a trend for improved disease free survival at 5 years 
(92.9% vs 61.8%; p=0.058). Twenty patients developed 
metastases during the FU (90% lung metastases). Two out of 
74 patients died. With a median FU of 46.4 months (range 6-
113 months) 12.8% of patients showed lymphedema, 10.8% 
had mild functional impairment and 5.4% reported reduced 
sensibility in the treated site.  
Conclusions: The preoperative approach allowed to irradiate 
smaller volumes compared to adjuvant RT and to deliver 
lower doses (50 Gy/25 fractions + 20 Gy boost only in case of 
positive margins, versus 60-66 Gy/30 fractions). Neoadjuvant 
RT produced a significant reduction of the tumor volume, 
allowing a less invasive and more conservative surgical 
approach, and high long-term local control rates. 
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